GA-map® COVID-19 Fecal Test
We have used our well-established technology platform and expertise in processing stool samples, to develop an RT-PCR assay that directly detects SARS-CoV-2 RNA.
Up to 50% of covid-19 patients experience gastrointestinal symptoms and problems
SARS-CoV-2 virus can be detected in stool samples, even weeks after that nasopharyngeal samples turned negative
A positive SARS-CoV-2 stool test may thus occur in an invidual with or without active COVID-19. Attention to thorough hand washing and other sanitary measures should be taken, especially after having used the restrooms. This aims to potentially reduce to spread of the virus through oral-fecal contamination.
GA-map® COVID-19 Fecal Test is suitable for:
Patients exhibiting signs and symptoms of COVID-19 (confirmation and management)
Patients in the recovery phase (surveillance)
Asymptomatic individuals concerned about possessing and transmitting the virus (prevention)
Combined with serology testing – quantitative IgG/IgM antibody testing – GA-map® COVID-19 Fecal Test could allow health professionals to strategically determine who may be able to safely return to work.
Important note: COVID-19 disease can only be diagnosed with positive SARS-CoV-2 results on a respiratory sample.
For information and order, please contact us at email@example.com
Ng SC, Tilg HCOVID-19 and the gastrointestinal tract: more than meets the eyeGut 2020;69:973-974.
Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020;323(18):1843–1844. doi:10.1001/jama.2020.3786
Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020;5(5):434-435.
Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020 Mar 3. pii: S0016-5085(20)30282-1. doi: 10.1053/j.gastro.2020.02.055. [correspondance]
Zheng Shufa, Fan Jian, Yu Fei, Feng Baihuan, Lou Bin, Zou Qianda et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study BMJ 2020; 369 :m1443